Atomy HemoHIM: A Comprehensive Overview of Research Findings

I. Preclinical Studies

A. Anti-inflammatory Activity

Research by Jo et al. (2007) demonstrated HemoHIM’s potent anti-inflammatory effects in various experimental models, including carrageenan-induced edema, cotton pellet-induced granuloma, and TNBS-induced colitis in rats.

B. Antioxidant and Anti-Fatigue Effects

Kwon et al. (2024) found that HemoHIM enhances swimming time, grip strength, and antioxidant enzyme expression in aged mice, potentially through modulation of the Nrf-2 signaling pathway.

C. Enhanced Antitumor Efficacy

Park et al. (2009) showed that HemoHIM enhances the antitumor effects of cisplatin in tumor-bearing mice, boosting NK and Tc cell activity while reducing cisplatin-induced kidney damage.

D. Toxicity Evaluation

Bak et al. (2024) conducted comprehensive toxicity studies, confirming the safety of HemoHIM G for use as a functional food ingredient based on the absence of significant toxicity or genotoxicity.

E. Immune Response Modulation

Park et al. (2012) demonstrated HemoHIM’s ability to ameliorate persistent down-regulation of Th1-like immune responses in fractionated γ-irradiated mice, possibly by modulating the IL-12p70/pSTAT4 signaling pathway.

F. Radiotherapy Enhancement

Park et al. (2010) found that HemoHIM enhances the therapeutic efficacy of ionizing radiation treatment in tumor-bearing mice by augmenting tumor weight reduction and increasing immune cell activity.

G. Polycystic Ovary Syndrome

Kim et al. (2009) reported that HemoHIM improves ovarian morphology and decreases expression of nerve growth factor in rats with steroid-induced polycystic ovaries.

H. Anti-obesity Potential

Roh et al. (2012) identified methyl gallate from HemoHIM as a promising anti-obesity agent, demonstrating its ability to inhibit lipid formation in adipocytes.

II. Clinical Trials

A. Ventilator-associated Pneumonia Prevention

Khamooshpour et al. (2024) conducted a randomized controlled trial showing that HemoHIM® supplementation may help prevent ventilator-associated pneumonia in ICU patients.

III. HemoHIM and Immune Modulation

Multiple studies have demonstrated HemoHIM’s immunomodulatory effects:

• Alleviating airway inflammation in COPD models (Shin et al., 2017)
• Enhancing dendritic cell maturation and T cell activation (Lee et al., 2016)
• Improving glucose tolerance and immune function in diabetic mice (Kim et al., 2014)
• Preventing airway inflammation by modulating Th1/Th2 cell differentiation (Kim et al., 2013)
• Counteracting cisplatin-induced immune suppression (Kim et al., 2019)

IV. HemoHIM and Radiation Protection

Several studies have shown HemoHIM’s protective effects against radiation:

• Protecting against radiation-induced intestinal injury (Kim et al., 2009)
• Safeguarding immune and hematopoietic systems against γ-irradiation (Park et al., 2014)
• Restoring immune functions in aged mice (Park et al., 2008)

V. HemoHIM and Cognitive Function

Kim et al. (2021) found that HemoHIM protects against scopolamine-induced amnesia in mice, potentially by increasing acetylcholine levels and inhibiting acetylcholinesterase in the hippocampus.

VI. HemoHIM Modifications and Synergistic Effects

Park et al. (2020) developed MH-30, a modified version of HemoHIM with increased fat-soluble polyphenols, demonstrating synergistic anticancer effects with cisplatin and reduced cisplatin-induced toxicity.